{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(2)"],"submitter":["Zhang J"],"pubmed_abstract":["Macrophages armed with chimeric antigen receptors (CARs) provide a potent new option for treating solid tumors. However, genetic engineering and scalable production of somatic macrophages remains significant challenges. Here, we used CRISPR-Cas9 gene editing methods to integrate an anti-GD2 CAR into the AAVS1 locus of human pluripotent stem cells (hPSCs). We then established a serum- and feeder-free differentiation protocol for generating CAR macrophages (CAR-Ms) through arterial endothelial-to-hematopoietic transition (EHT). CAR-M produced by this method displayed a potent cytotoxic activity against GD2-expressing neuroblastoma and melanoma in vitro and neuroblastoma in vivo. This study provides a new platform for the efficient generation of off-the-shelf CAR-Ms for antitumor immunotherapy."],"journal":["Stem cell reports"],"pagination":["585-596"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9968983"],"repository":["biostudies-literature"],"pubmed_title":["Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies."],"pmcid":["PMC9968983"],"pubmed_authors":["Swanson S","Zhang J","Bolin J","Bernstein MN","Steill J","Stewart R","Forsberg MH","Thomson JA","Majumder A","Capitini CM","Slukvin II","Duffin B","Webster S","Brown ME"],"additional_accession":[]},"is_claimable":false,"name":"Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies.","description":"Macrophages armed with chimeric antigen receptors (CARs) provide a potent new option for treating solid tumors. However, genetic engineering and scalable production of somatic macrophages remains significant challenges. Here, we used CRISPR-Cas9 gene editing methods to integrate an anti-GD2 CAR into the AAVS1 locus of human pluripotent stem cells (hPSCs). We then established a serum- and feeder-free differentiation protocol for generating CAR macrophages (CAR-Ms) through arterial endothelial-to-hematopoietic transition (EHT). CAR-M produced by this method displayed a potent cytotoxic activity against GD2-expressing neuroblastoma and melanoma in vitro and neuroblastoma in vivo. This study provides a new platform for the efficient generation of off-the-shelf CAR-Ms for antitumor immunotherapy.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-18T14:22:16.876Z","creation":"2025-04-07T00:30:37.491Z"},"accession":"S-EPMC9968983","cross_references":{"pubmed":["36638788"],"doi":["10.1016/j.stemcr.2022.12.012"]}}